Skip to content
Austin Top 50
Author:
Starton Therapeutics Inc.
Arthur J. Gallagher & Co. Announces First Quarter 2026 Financial Results
May 12, 2026
Starton Therapeutics Files Patent Applications for the Use of CAR-T Cell Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formulation of Lenalidomide, for the Treatment of Blood Cancer
March 5, 2026